Free Trial
→ Do NOT Day Trade (Do THIS instead) (From Monument Traders Alliance) (Ad)tc pixel
NASDAQ:LYEL

Lyell Immunopharma Q2 2024 Earnings Report

Lyell Immunopharma logo
$12.82 -0.48 (-3.61%)
Closing price 04:00 PM Eastern
Extended Trading
$12.84 +0.03 (+0.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Lyell Immunopharma EPS Results

Actual EPS
-$3.60
Consensus EPS
-$4.00
Beat/Miss
Beat by +$0.40
One Year Ago EPS
N/A

Lyell Immunopharma Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lyell Immunopharma Announcement Details

Quarter
Q2 2024
Date
8/7/2024
Time
After Market Closes
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Lyell Immunopharma's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Lyell Immunopharma's Q2 2024 Press ReleasePress Release
(8-K)
Lyell Immunopharma's Q2 2024 Quarterly reportQuarterly report
(10-Q)

Lyell Immunopharma Earnings Headlines

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering ...
September 3, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/lyell-immunopharma-announces-the-initiation-of-a-phase-3-head-to-head-car-t-cell-therapy-clinical-trial-in-aggressive-large-b-cell-lymphoma-and-formation-of-expert-steering-committee-1035110090
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
September 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/03/3143517/0/en/lyell-immunopharma-announces-the-initiation-of-a-phase-3-head-to-head-car-t-cell-therapy-clinical-trial-in-aggressive-large-b-cell-lymphoma-and-formation-of-expert-steering-committ.html
Do NOT Day Trade (Do THIS instead)
Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shocking way to take 100% certain events (mandated by the U.S. Government)...tc pixel
September 12 at 2:00 AM  |  Monument Traders Alliance (Ad)
Lyell Immunopharma Announces Participation in September Investor Conferences
September 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/02/3143147/0/en/lyell-immunopharma-announces-participation-in-september-investor-conferences.html
Lyell Immunopharma (NASDAQ:LYEL) Upgraded to Hold at Wall Street Zen
September 2, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30307973
Lyell Immunopharma Advances CAR T-Cell Therapies
August 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/lyell-immunopharma-advances-car-t-cell-therapies/ar-AA1KuJ9A
See More Lyell Immunopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lyell Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyell Immunopharma and other key companies, straight to your email.

About Lyell Immunopharma

Lyell Immunopharma (NASDAQ:LYEL) is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers. Early-stage candidates utilize technologies aimed at epigenetic reprogramming of T cells to improve their ability to expand, traffic to tumor sites and maintain durable anti-tumor activity. Lyell partners with academic centers and contract research organizations to advance its lead programs through IND-enabling studies and into clinical trials.

Founded in 2017 and headquartered in South San Francisco, Lyell Immunopharma was established by a team of immunologists and cell therapy experts. The company has raised venture funding from leading life science investors and maintains research and manufacturing operations in the San Francisco Bay Area. Under the leadership of co-founder and CEO David Chang, Lyell is building a translational research engine designed to accelerate the discovery, development and manufacturing of engineered T cell products for patients with high-unmet-need cancers.

View Lyell Immunopharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles